WHWK · XBRL financial data

Whitehawk Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (WHWK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	15,000	1,120	15,216	24,354	25,983	7,145
Cost of goods and services sold	—	0	1,335	2,809	3,024	760
Research and development	12,595	19,670	32,662	48,929	51,030	90,963
Selling, general and administrative	—	18,511	40,176	44,549	36,749	29,822
General and administrative	8,762	18,511	—	—	—	—
Total operating expenses	21,357	112,337	—	—	—	—
Operating income (loss)	(6,357)	(111,217)	(62,681)	(71,933)	(67,458)	(114,400)
Interest income	41	13	2,398	6,400	3,925	6,231
Interest expense	815	665	230	231	154	0
Other income (expense)	(927)	1,129	2,168	6,168	3,767	93,804
Income tax expense (benefit)	2	2	0	0	0	0
Net income (loss)	(4,315)	(110,090)	(60,513)	(65,765)	(63,691)	(20,596)
Earnings per share, basic USD per share	—	(12.41)	(2.69)	(2.44)	(2.36)	(0.33)
Earnings per share, diluted USD per share	—	(12.41)	(2.69)	(2.44)	(2.36)	(0.33)
Weighted average shares, basic thousands of shares	—	8,923	22,511	26,918	27,030	61,887
Weighted average shares, diluted thousands of shares	—	8,923	22,511	26,918	27,030	61,887

Fiscal years (WHWK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	42,605	148,989	39,019	62,888	28,670	37,568
Short-term investments	—	0	133,541	45,957	18,567	108,129
Accounts receivable	14,149	0	1,862	5,488	5,903	0
Inventory	—	0	1,861	6,427	5,311	0
Prepaid and other current assets	81	2,283	3,746	3,826	2,836	3,316
Total current assets	44,719	151,272	180,029	124,586	61,287	149,013
Property and equipment, net	122	57	508	4,802	6,846	3
Right-of-use asset	64	557	1,522	1,169	787	0
Total assets	44,925	157,910	184,237	132,423	70,319	150,830
Accounts payable	523	6,439	3,519	5,898	2,159	917
Accrued liabilities	4,099	8,445	14,922	14,306	14,647	13,602
Total current liabilities	1,867	15,273	18,835	26,395	17,074	14,519
Lease liability, non-current	—	474	1,267	833	565	0
Total liabilities	1,867	21,504	25,859	27,228	17,841	14,519
Accumulated deficit	(146,551)	(142,685)	(203,198)	(268,963)	(332,654)	(353,250)
Total stockholders' equity	43,058	136,406	158,378	105,195	52,478	136,311
Total liabilities and equity	44,925	157,910	184,237	132,423	70,319	150,830
Common shares outstanding (cover page) thousands of shares	47,313	20,930	24,437	24,554	46,785	47,197

Fiscal years (WHWK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(4,315)	(110,090)	(60,513)	(65,765)	(63,691)	(20,596)
Stock-based compensation	1,282	2,106	9,643	11,954	10,839	9,873
Depreciation and amortization	9	105	159	169	193	79
Net cash from operating activities	(5,385)	(22,423)	(49,640)	(59,663)	(59,550)	(97,433)
Purchases of property and equipment	19	46	444	3,972	1,654	552
Net cash from investing activities	(19)	25,153	(132,886)	83,206	25,202	11,891
Proceeds from issuing common stock	9,744	155,000	0	—	—	—
Dividends paid	—	4,412	0	—	—	—
Net cash from financing activities	9,484	141,804	72,620	326	130	94,376
Net change in cash	4,080	144,534	(109,906)	23,869	(34,218)	8,834

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	15,594	736	(22,394)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Oncolytics Biotech	4,115	not reported	(8,138)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.